Adolor Corp. lost almost half its value Tuesday after reporting results from three trials evaluating Entereg (alvimopan) for opioid-induced bowel dysfunction. Two of the trials failed to meet the primary endpoint, including one study designed to support a new drug application filing in the middle of 2007. (BioWorld Today) Read More
